Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert Consensus: JACC Journals 🥸 Ariela Orkaby MD MPH introduced me to @DrNikkiBart - and this turned out to be a great project 😱From American College of Cardiology geriatric cardiology leadership council: Summary 👇👇👇

Congrats Suzanne Lentzsch, MD, PhD ! So well Deserved!

Congrats Sagar Lonial MD ! Well deserved!

#Myeloma Paper of the Day: Panel on cardiac #amyloidosis in older adults concludes frailty is dynamic & modifiable; interventions = structured exercise (resistance exercise, flexibility, balance & aerobic training), nutrition & psychosocial support: pubmed.ncbi.nlm.nih.gov/40373524/. #mmsm

Disappointed to be notified of negative outcome of birtamimab. Many patients enrolled at our center in the hope of effect. Hopefully correlative studies will shed some light. We will continue to push forward for novel effective therapies for patients with #amyloidosis.

Disappointed by negative outcome of birtamimab. Many patients enrolled at our center in the hope of effect. Hopefully correlative studies will shed some light. We will continue to push forward for novel effective therapies for patients with #amyloidosis.

Congratulations to the The Bank of Korea for hosting the 20th edition its International Conference and many thanks for having me! Great conference and perfectly organized

Could not agree more Raj Chakraborty ! I share same concerns around short and long term side effects of CAR-T as compared to BiTE. Length of response in amyloidosis is also key. Hope to share early data about our prospective elra trial in amyloidosis at ASH! Going strong!

Thank you to Francesco Bianchi and all participants for creating with us another great “Advances in Structural Shocks Identification" workshop at the Barcelona School of Economics Summer Forum. Great presentations, great interactions, and a friendly dinner!

ASH is committing more than $12 million to address research funding challenges and support the next generation of hematologists. Learn more: ow.ly/sK3050W735W #Fight4Hematology

A labor of love! Excited to see this online first. #amyloidosis. It was a treat to collaborate with many friends: Allon Klein Lab, Ray Comenzo, Mario Nuvolone, Niccolo Bolli, Joao Paulo Gygi Lab. Thanks Blood Journals Portfolio! ashpublications.org/blood/article-…

Thanks Maria Moscvin. And another paper for you, rising star in plasma cell dyscrasia:) you were there from the beginning!

Way to go Maria Moscvin ! Congratulations and so well deserved.

I know one really well!!! Francesco Bianchi #proudsister

Thrilled to share our new work out today on Blood Journals Portfolio #Blood where we described the role of pPCs in the TME of PCs dyscrasias! Check it out! Niccolo Bolli #FrancyLazzaroni Antonio Matera Policlinico di Milano Università degli Studi di Milano Tom Cupedo

I could not be more proud! Domenico Giannone, the king of nowcasting and simply a superb econometrician, has just joined Johns Hopkins University as a Bloomberg Distinguished Professor. Welcome to JHU Domenico!

Thanks Robert Z. Orlowski ! It was great to collaborate with Raj Chakraborty and Suzanne Lentzsch, MD, PhD for this initial report of clinical activity of elranatamab in patients with AL amyloidosis. Our prospective study of Elra in relapsed/refractory disease is rapidly accruing at Dana-Farber

Thanks Raj Chakraborty. What an amazing option for our patients with AL amyloidosis! More to come from our multicenter, prospective study of elra for relapsed/refractory disease Dana-Farber. #amyloidosis.

Thanks Muzaffar Qazilbash ! We are excited to make this highly effective treatment option available to AL amyloidosis patients through a prospective clinical trial Dana-Farber, shortly opening at other centers in the US. #amyloidosis

Congrats Sri!!!